News

Sun Pharma Advanced Research Company Ltd. submitted a confirmation certificate to the National Stock Exchange of India Ltd. and BSE Limited for the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with MUFG Intime (India) Private Limited acting as the Registrar and Share Transfer Agent.

Sun Pharma Advanced Research Company Limited informed the National Stock Exchange of India Ltd. and BSE Limited that the trading window for dealing in the company’s shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half year ended September 30, 2026.

Net Loss of Sun Pharma Advanced Research Company reported to Rs 20.78 crore in the quarter ended June 2026 as against net loss of Rs 51.87 crore during the previous quarter ended June 2025. Sales rose 314.11% to Rs 39.92 crore in the quarter ended June 2026 as against Rs 9.64 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales39.929.64 314 OPM %-85.17-540.25 - PBDT-18.47-49.13 62 PBT-20.67-51.81 60 NP-20.78-51.87 60 Powered by Capital Market - Live News

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 10 August 2026.

Sun Pharma Advanced Research Company announced that the 21th Annual General Meeting(AGM) of the company will be held on 10 August 2026.